Joel Beatty
Stock Analyst at Baird
(4.47)
# 322
Out of 4,996 analysts
198
Total ratings
47.8%
Success rate
26.56%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $36.71 | +82.51% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $3.24 | +85.19% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $14.16 | -36.44% | 6 | Jul 8, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $129.77 | +11.74% | 8 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $21.05 | +47.27% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $17.82 | +34.68% | 5 | May 16, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $712.03 | -4.50% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $13.95 | +107.89% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $58.99 | +11.88% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $127.00 | +22.05% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $116.76 | +38.75% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $27.89 | +47.01% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $5.10 | +96.27% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $10.67 | +49.95% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $11.92 | +34.23% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $52.02 | +40.33% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $19.52 | +63.93% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $52.72 | +42.26% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $14.52 | -24.24% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.73 | +305.21% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $53.85 | +20.71% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $29.08 | +147.59% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.57 | +15,186.62% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.29 | +248.84% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $8.93 | +179.96% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.35 | +2,471.43% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $15.68 | +78.57% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.01 | +696.02% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.76 | -28.98% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.52 | +2,794.74% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $32.80 | +76.83% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $26.83 | -10.55% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $22.17 | -18.81% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.06 | +191.26% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.49 | +410.02% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $446.40 | -60.80% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $5.10 | +174.51% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $18.36 | +488.24% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $64.09 | +21.70% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $9.16 | +991.70% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $16.00 | +650.00% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.46 | +12,905.78% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.65 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $8.55 | +75.44% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.39 | +30,434.35% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $9.05 | +109.94% | 3 | Nov 10, 2017 |
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $36.71
Upside: +82.51%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $3.24
Upside: +85.19%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $14.16
Upside: -36.44%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $129.77
Upside: +11.74%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $21.05
Upside: +47.27%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $17.82
Upside: +34.68%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $712.03
Upside: -4.50%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $13.95
Upside: +107.89%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $58.99
Upside: +11.88%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $127.00
Upside: +22.05%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $116.76
Upside: +38.75%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $27.89
Upside: +47.01%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $5.10
Upside: +96.27%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $10.67
Upside: +49.95%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $11.92
Upside: +34.23%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $52.02
Upside: +40.33%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $19.52
Upside: +63.93%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $52.72
Upside: +42.26%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $14.52
Upside: -24.24%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.73
Upside: +305.21%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $53.85
Upside: +20.71%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $29.08
Upside: +147.59%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.57
Upside: +15,186.62%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.29
Upside: +248.84%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $8.93
Upside: +179.96%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.35
Upside: +2,471.43%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $15.68
Upside: +78.57%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $2.01
Upside: +696.02%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.76
Upside: -28.98%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.52
Upside: +2,794.74%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $32.80
Upside: +76.83%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $26.83
Upside: -10.55%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $22.17
Upside: -18.81%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.06
Upside: +191.26%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.49
Upside: +410.02%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $446.40
Upside: -60.80%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $5.10
Upside: +174.51%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $18.36
Upside: +488.24%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $64.09
Upside: +21.70%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $9.16
Upside: +991.70%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $16.00
Upside: +650.00%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.46
Upside: +12,905.78%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.65
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $8.55
Upside: +75.44%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.39
Upside: +30,434.35%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $9.05
Upside: +109.94%